Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 277 to 284 of 284 entries
Sorted by: Best Match Show Resources per page
Antithrombotic Therapy for Stroke Prevention in Patients With Ischemic Stroke With Aspirin Treatment Failure.

Stroke

Lusk JB, Xu H, Peterson ED, Bhatt DL, Fonarow GC, Smith EE, Matsouaka R, Schwamm LH, Xian Y.
PMID: 34702067
Stroke. 2021 Dec;52(12):e777-e781. doi: 10.1161/STROKEAHA.121.034622. Epub 2021 Oct 27.

BACKGROUND AND PURPOSE: Many older patients presenting with acute ischemic stroke were already taking aspirin before admission. However, the management strategy for patients with aspirin treatment failure has not been fully established.METHODS: We used data from the American Heart...

Cite
Lusk JB, Xu H, Peterson ED, et al. Antithrombotic Therapy for Stroke Prevention in Patients With Ischemic Stroke With Aspirin Treatment Failure. Stroke. 2021;52(12):e777-e781doi: 10.1161/STROKEAHA.121.034622.
Lusk, J. B., Xu, H., Peterson, E. D., Bhatt, D. L., Fonarow, G. C., Smith, E. E., Matsouaka, R., Schwamm, L. H., & Xian, Y. (2021). Antithrombotic Therapy for Stroke Prevention in Patients With Ischemic Stroke With Aspirin Treatment Failure. Stroke, 52(12), e777-e781. https://doi.org/10.1161/STROKEAHA.121.034622
Lusk, Jay B, et al. "Antithrombotic Therapy for Stroke Prevention in Patients With Ischemic Stroke With Aspirin Treatment Failure." Stroke vol. 52,12 (2021): e777-e781. doi: https://doi.org/10.1161/STROKEAHA.121.034622
Lusk JB, Xu H, Peterson ED, Bhatt DL, Fonarow GC, Smith EE, Matsouaka R, Schwamm LH, Xian Y. Antithrombotic Therapy for Stroke Prevention in Patients With Ischemic Stroke With Aspirin Treatment Failure. Stroke. 2021 Dec;52(12):e777-e781. doi: 10.1161/STROKEAHA.121.034622. Epub 2021 Oct 27. PMID: 34702067; PMCID: PMC8608737.
Copy Download .nbib Format: NLM
Balancing Benefits and Risks of Long-Term Antiplatelet Therapy in Noncardioembolic Transient Ischemic Attack or Stroke.

Stroke

Hilkens NA, Algra A, Diener HC, Bath PM, Csiba L, Hacke W, Kappelle LJ, Koudstaal PJ, Leys D, Mas JL, Sacco RL, Greving JP.
PMID: 34304604
Stroke. 2021 Oct;52(10):3258-3265. doi: 10.1161/STROKEAHA.120.031755. Epub 2021 Jul 26.

BACKGROUND AND PURPOSE: Lifelong treatment with antiplatelet drugs is recommended following a transient ischemic attack or ischemic stroke. Bleeding complications may offset the benefit of antiplatelet drugs in patients at increased risk of bleeding and low risk of recurrent...

Cite
Hilkens NA, Algra A, Diener HC, et al. Balancing Benefits and Risks of Long-Term Antiplatelet Therapy in Noncardioembolic Transient Ischemic Attack or Stroke. Stroke. 2021;52(10):3258-3265doi: 10.1161/STROKEAHA.120.031755.
Hilkens, N. A., Algra, A., Diener, H. C., Bath, P. M., Csiba, L., Hacke, W., Kappelle, L. J., Koudstaal, P. J., Leys, D., Mas, J. L., Sacco, R. L., & Greving, J. P. (2021). Balancing Benefits and Risks of Long-Term Antiplatelet Therapy in Noncardioembolic Transient Ischemic Attack or Stroke. Stroke, 52(10), 3258-3265. https://doi.org/10.1161/STROKEAHA.120.031755
Hilkens, Nina A, et al. "Balancing Benefits and Risks of Long-Term Antiplatelet Therapy in Noncardioembolic Transient Ischemic Attack or Stroke." Stroke vol. 52,10 (2021): 3258-3265. doi: https://doi.org/10.1161/STROKEAHA.120.031755
Hilkens NA, Algra A, Diener HC, Bath PM, Csiba L, Hacke W, Kappelle LJ, Koudstaal PJ, Leys D, Mas JL, Sacco RL, Greving JP. Balancing Benefits and Risks of Long-Term Antiplatelet Therapy in Noncardioembolic Transient Ischemic Attack or Stroke. Stroke. 2021 Oct;52(10):3258-3265. doi: 10.1161/STROKEAHA.120.031755. Epub 2021 Jul 26. PMID: 34304604; PMCID: PMC8478107.
Copy Download .nbib Format: NLM
Tenofovir Modulates Semaphorin 4D Signaling and Regulates Bone Homeostasis, Which Can Be Counteracted by Dipyridamole and Adenosine A2A Receptor.

International journal of molecular sciences

Llamas-Granda P, Martin-Rodríguez L, Largo R, Herrero-Beaumont G, Mediero A.
PMID: 34768920
Int J Mol Sci. 2021 Oct 25;22(21). doi: 10.3390/ijms222111490.

Semaphorin 4D (Sema4D) is a neurotrophin that is secreted by osteoclasts and binds to its receptor PlexinB1 on osteoblasts to inhibit their differentiation and function. Adenosine A2A activation inhibits osteoclast Sema4D-mediated secretion, diminishes inflammatory osteolysis and prevents bone loss...

Cite
Llamas-Granda P, Martin-Rodríguez L, Largo R, et al. Tenofovir Modulates Semaphorin 4D Signaling and Regulates Bone Homeostasis, Which Can Be Counteracted by Dipyridamole and Adenosine A2A Receptor. Int J Mol Sci. 2021;22(21)doi: 10.3390/ijms222111490.
Llamas-Granda, P., Martin-Rodríguez, L., Largo, R., Herrero-Beaumont, G., & Mediero, A. (2021). Tenofovir Modulates Semaphorin 4D Signaling and Regulates Bone Homeostasis, Which Can Be Counteracted by Dipyridamole and Adenosine A2A Receptor. International journal of molecular sciences, 22(21), . https://doi.org/10.3390/ijms222111490
Llamas-Granda, Patricia, et al. "Tenofovir Modulates Semaphorin 4D Signaling and Regulates Bone Homeostasis, Which Can Be Counteracted by Dipyridamole and Adenosine A2A Receptor." International journal of molecular sciences vol. 22,21 (2021). doi: https://doi.org/10.3390/ijms222111490
Llamas-Granda P, Martin-Rodríguez L, Largo R, Herrero-Beaumont G, Mediero A. Tenofovir Modulates Semaphorin 4D Signaling and Regulates Bone Homeostasis, Which Can Be Counteracted by Dipyridamole and Adenosine A2A Receptor. Int J Mol Sci. 2021 Oct 25;22(21). doi: 10.3390/ijms222111490. PMID: 34768920; PMCID: PMC8583797.
Copy Download .nbib Format: NLM
Giant bilateral axillary artery aneurysms with left complete obstructive thrombus in intravenous immunoglobulin-sensitive Kawasaki disease: a case report.

Pediatric rheumatology online journal

Chu C, He L, Lin YX, Xie LP, Liu F.
PMID: 34749768
Pediatr Rheumatol Online J. 2021 Nov 08;19(1):157. doi: 10.1186/s12969-021-00643-w.

BACKGROUND: Kawasaki disease (KD) is a systemic vasculitis that predominantly affects medium-sized arteries. In addition to well-known coronary artery aneurysms (CAAs), peripheral systemic artery aneurysms (SAAs) have also been sporadically reported. In the literatures, SAAs occurred mainly in untreated,...

Cite
Chu C, He L, Lin YX, et al. Giant bilateral axillary artery aneurysms with left complete obstructive thrombus in intravenous immunoglobulin-sensitive Kawasaki disease: a case report. Pediatr Rheumatol Online J. 2021;19(1):157doi: 10.1186/s12969-021-00643-w.
Chu, C., He, L., Lin, Y. X., Xie, L. P., & Liu, F. (2021). Giant bilateral axillary artery aneurysms with left complete obstructive thrombus in intravenous immunoglobulin-sensitive Kawasaki disease: a case report. Pediatric rheumatology online journal, 19(1), 157. https://doi.org/10.1186/s12969-021-00643-w
Chu, Chen, et al. "Giant bilateral axillary artery aneurysms with left complete obstructive thrombus in intravenous immunoglobulin-sensitive Kawasaki disease: a case report." Pediatric rheumatology online journal vol. 19,1 (2021): 157. doi: https://doi.org/10.1186/s12969-021-00643-w
Chu C, He L, Lin YX, Xie LP, Liu F. Giant bilateral axillary artery aneurysms with left complete obstructive thrombus in intravenous immunoglobulin-sensitive Kawasaki disease: a case report. Pediatr Rheumatol Online J. 2021 Nov 08;19(1):157. doi: 10.1186/s12969-021-00643-w. PMID: 34749768; PMCID: PMC8573567.
Copy Download .nbib Format: NLM
Myocardial contractility improvement after coronary artery by-pass grafting in a 1-year observation: The role of myocardial viability assessment.

Cardiology journal

Knapp M, Musiał WJ, Lisowska A, Hinrle T.
PMID: 18651468
Cardiol J. 2007;14(3):246-51.

BACKGROUND: Left ventricular (LV) contractility impairment in coronary artery disease patients may be the effect of heart muscle hibernation due to chronic ischemia. Revascularization is the only method to restore contractile function in these patients. The time and degree...

Cite
Knapp M, Musiał WJ, Lisowska A, et al. Myocardial contractility improvement after coronary artery by-pass grafting in a 1-year observation: The role of myocardial viability assessment. Cardiol J. 2007;14(3):246-51
Knapp, M., Musiał, W. J., Lisowska, A., & Hinrle, T. (2007). Myocardial contractility improvement after coronary artery by-pass grafting in a 1-year observation: The role of myocardial viability assessment. Cardiology journal, 14(3), 246-51.
Knapp, Małgorzata, et al. "Myocardial contractility improvement after coronary artery by-pass grafting in a 1-year observation: The role of myocardial viability assessment." Cardiology journal vol. 14,3 (2007): 246-51.
Knapp M, Musiał WJ, Lisowska A, Hinrle T. Myocardial contractility improvement after coronary artery by-pass grafting in a 1-year observation: The role of myocardial viability assessment. Cardiol J. 2007;14(3):246-51. PMID: 18651468.
Copy Download .nbib Format: NLM
Left ventricular contractile reserve as a determinant of adverse clinical outcomes: a systematic review.

Internal medicine journal

Thein PM, Mirzaee S, Cameron JD, Nasis A.
PMID: 35015318
Intern Med J. 2022 Jan 11; doi: 10.1111/imj.14995. Epub 2022 Jan 11.

An abnormal left ventricular contractile reserve is often seen in patients undergoing stress echocardiogram and may indicate the presence of obstructive coronary artery disease. The techniques and indexes used to identify abnormal left ventricular contractile response and its prognostic...

Cite
Thein PM, Mirzaee S, Cameron JD, et al. Left ventricular contractile reserve as a determinant of adverse clinical outcomes: a systematic review. Intern Med J. 2022;doi: 10.1111/imj.14995.
Thein, P. M., Mirzaee, S., Cameron, J. D., & Nasis, A. (2022). Left ventricular contractile reserve as a determinant of adverse clinical outcomes: a systematic review. Internal medicine journal, . https://doi.org/10.1111/imj.14995
Thein, Paul M, et al. "Left ventricular contractile reserve as a determinant of adverse clinical outcomes: a systematic review." Internal medicine journal vol. (2022). doi: https://doi.org/10.1111/imj.14995
Thein PM, Mirzaee S, Cameron JD, Nasis A. Left ventricular contractile reserve as a determinant of adverse clinical outcomes: a systematic review. Intern Med J. 2022 Jan 11; doi: 10.1111/imj.14995. Epub 2022 Jan 11. PMID: 35015318.
Copy Download .nbib Format: NLM
Fasted Intestinal Solubility Limits and Distributions Applied to the Biopharmaceutics and Developability Classification Systems.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V

Abuhassan Q, Khadra I, Pyper K, Augustijns P, Brouwers J, Halbert GW.
PMID: 34923138
Eur J Pharm Biopharm. 2021 Dec 16; doi: 10.1016/j.ejpb.2021.12.006. Epub 2021 Dec 16.

After oral administration, a drug's solubility in intestinal fluid is an important parameter influencing bioavailability and if the value is known it can be applied to estimate multiple biopharmaceutical parameters including the solubility limited absorbable dose. Current in vitro...

Cite
Abuhassan Q, Khadra I, Pyper K, et al. Fasted Intestinal Solubility Limits and Distributions Applied to the Biopharmaceutics and Developability Classification Systems. Eur J Pharm Biopharm. 2021;doi: 10.1016/j.ejpb.2021.12.006.
Abuhassan, Q., Khadra, I., Pyper, K., Augustijns, P., Brouwers, J., & Halbert, G. W. (2021). Fasted Intestinal Solubility Limits and Distributions Applied to the Biopharmaceutics and Developability Classification Systems. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, . https://doi.org/10.1016/j.ejpb.2021.12.006
Abuhassan, Qamar, et al. "Fasted Intestinal Solubility Limits and Distributions Applied to the Biopharmaceutics and Developability Classification Systems." European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V vol. (2021). doi: https://doi.org/10.1016/j.ejpb.2021.12.006
Abuhassan Q, Khadra I, Pyper K, Augustijns P, Brouwers J, Halbert GW. Fasted Intestinal Solubility Limits and Distributions Applied to the Biopharmaceutics and Developability Classification Systems. Eur J Pharm Biopharm. 2021 Dec 16; doi: 10.1016/j.ejpb.2021.12.006. Epub 2021 Dec 16. PMID: 34923138.
Copy Download .nbib Format: NLM
Cardiac magnetic resonance imaging for the diagnosis of coronary artery disease: an evidence-based analysis.

Ontario health technology assessment series

[No authors listed]
PMID: 23074389
Ont Health Technol Assess Ser. 2010;10(12):1-38. Epub 2010 Jun 01.

UNLABELLED: In July 2009, the Medical Advisory Secretariat (MAS) began work on Non-Invasive Cardiac Imaging Technologies for the Diagnosis of Coronary Artery Disease (CAD), an evidence-based review of the literature surrounding different cardiac imaging modalities to ensure that appropriate...

Cite
Cardiac magnetic resonance imaging for the diagnosis of coronary artery disease: an evidence-based analysis. Ont Health Technol Assess Ser. 2010;10(12):1-38
(2010). Cardiac magnetic resonance imaging for the diagnosis of coronary artery disease: an evidence-based analysis. Ontario health technology assessment series, 10(12), 1-38.
"Cardiac magnetic resonance imaging for the diagnosis of coronary artery disease: an evidence-based analysis." Ontario health technology assessment series vol. 10,12 (2010): 1-38.
Cardiac magnetic resonance imaging for the diagnosis of coronary artery disease: an evidence-based analysis. Ont Health Technol Assess Ser. 2010;10(12):1-38. Epub 2010 Jun 01. PMID: 23074389; PMCID: PMC3377522.
Copy Download .nbib Format: NLM
Showing 277 to 284 of 284 entries